Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC

NCT01761240 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Pancreatic Cancer
Colorectal Cancer
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma

Interventions

DRUG: MORAb-066

Sponsor

Morphotek

Collaborators

[object Object]